Edition:
United States

Xencor Inc (XNCR.OQ)

XNCR.OQ on NASDAQ Stock Exchange Global Market

40.10USD
22 Jun 2018
Change (% chg)

$0.17 (+0.43%)
Prev Close
$39.93
Open
$40.00
Day's High
$40.46
Day's Low
$39.06
Volume
1,112,959
Avg. Vol
143,767
52-wk High
$43.29
52-wk Low
$19.00

Select another date:

Mon, May 7 2018

BRIEF-Xencor Reports Q1 Loss Per Share $0.62

* Q1 EARNINGS PER SHARE VIEW $-0.46 -- THOMSON REUTERS I/B/E/S

BRIEF-Xencor Says Public Offering Of 7.30 Mln Common Shares Priced At $31 Per Share

* XENCOR ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK

BRIEF-Xencor Files For Potential Mixed Shelf Offering

* XENCOR INC FILES FOR POTENTIAL MIXED SHELF OFFERING; SIZE NOT DISCLOSED- SEC FILING ‍​ Source text: (http://bit.ly/2G8MdV1) Further company coverage:

BRIEF-Xencor Announces Proposed Public Offering Of Common Stock

* XENCOR, INC. ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK

BRIEF-Xencor Reports Q4 Loss Per Share $0.25

* XENCOR REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS

BRIEF-Xencor Doses First Patient In Phase 1 Study Of Xmab®18087,An Antibody For Treatment Of Neuroendocrine Tumors And Gastrointestinal Stromal Tumors

* XENCOR DOSES FIRST PATIENT IN PHASE 1 STUDY OF XMAB®18087 BISPECIFIC TUMOR TARGETING ANTIBODY FOR THE TREATMENT OF NEUROENDOCRINE TUMORS AND GASTROINTESTINAL STROMAL TUMORS

BRIEF-Xencor Inc - Expect Initial Data From Phase 2 Trial Of Xmab®5871 In Systemic Lupus Erythematosus

* XENCOR INC - EXPECT INITIAL DATA FROM PHASE 2 TRIAL OF XMAB®5871 IN SYSTEMIC LUPUS ERYTHEMATOSUS

Select another date: